Exelixis Presents 5-year Follow-Up Data from P-III (CheckMate -9ER) of Cabometyx + Opdivo in Renal Cell Carcinoma Patients at ASCO GU 2025
Shots:
- The P-III (CheckMate -9ER) trial assessed Cabometyx + Opdivo vs sunitinib in 651 pts with previously untreated advanced RCC
- At 67.6mos. mFU, study showed improved mPFS (16.4 vs 8.3mos.), OS (46.5 vs 35.5mos.), ORR (55.7% vs 27.4%) & DOR (22 vs 15.2mos.), while in IMDC risk groups: favorable (n=146; mPFS: 21.4 vs 12.8mos.; mOS: 53.7 vs 58.9mos.; ORR: 66.2% vs 43.1%) & intermediate/poor (n=505; mPFS: 15.4 vs 7.1mos.; mOS: 43.9 vs 29.2mos.; ORR: 52.6% vs 23%)
- Analysis of metastases subgroups showed: liver (n=129; mPFS: 10.9 vs 6.2mos. mOS: 37.6 vs 22.1mos. ORR: 52.1% vs 21.4%), bone (n=154; mPFS: 13.8 vs 5.3mos. mOS: 34.8 vs 20.7mos. ORR: 49.4% vs 9.3%), & lung (n=492; mPFS: 16.4 vs 8.3mos. mOS: 47.5 vs 32.4mos. ORR: 57.3% vs 27.9%)
Ref: Businesswire | Image: Exelixis
Related News:- Exelixis and Merck Join Forces to Develop Zanzalintinib for Head and Neck Cancer and Renal Cell Carcinoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
